In a 14-year period in a single institution 31 autografts were performed in 26 patients with multiple myeloma (MM), using a simplified and affordable autografting procedure: conducting the grafts on an outpatient basis and avoiding stem cell freezing. Autografts were started on an outpatient basis in all instances, but four patients were admitted to the hospital. Median time to achieve more than 0.5 Â 10 9 /l granulocytes was 27 days, whereas median time to recover above 20 Â 10 9 /l plts was 37 days. CR was achieved in 19 cases and a very good partial response in 6 cases. The 100-day mortality was 9.6%. The overall median post-transplant survival has not been reached, being above 76 months, whereas the 76-month survival is 80%. The median cost of each procedure was US$ 15 000. Survival results were substantially better than those of historical control in a group of patients treated in the same institution with melphalan/prednisone. It is concluded that high-dose therapy rescued with a simplified autologous stem cell graft is a valid, useful and affordable therapeutic option for patients with MM, even with economical restraints.
Introduction
Multiple myeloma (MM) represents a plasma cell disorder associated with an accumulation of monoclonal, terminally differentiated plasma cells in the BM and, usually, the presence of a monoclonal Ig in the blood and/or urine. 1 It accounts for B1% of all malignant diseases and is the second most commonly diagnosed hematological malignancy, with an annual incidence in Europe of 23 000 new cases. 1 The incidence is higher with increasing age with only 3% of all patients being younger than 40 years. The recorded incidence of myeloma has been increasing in many countries, but these reported increases are, in part, because of increasing diagnostic accuracy. 1, 2 MM occurs in all races, but rates are higher in African American and lower in Asian and Mexican populations. 3, 4 The median survival from diagnosis of individuals with MM treated with conventional chemotherapy is 3-4 years; 4 ,5 the introduction of high-dose chemotherapy with stem cell rescue has led to improved survival, but patients eventually experience disease relapse, so that MM remains an incurable disease. 1, 2 Data from the Mayo Clinic show that the overall survival of patients did not improve from 1985 through 1998, 2 whereas data from the MD Anderson Cancer Center show the same result for the period from 1965 to 1991. 4 However, in the past years, survival seems to be improving significantly, probably as a result of the combined use of SCT, thalidomide, new agents such as bortezomib or lenalidomide and supportive care. 1, 2, 4, 6 We report here the long-term results of the treatment of a group of 26 patients with MM treated with a simplified autografting procedure in a single institution (Clı´nica RUIZ de Puebla, Me´xico) in a 14-year period, which indicate that the prognosis of patients with MM has improved substantially since the introduction of high-dose therapy rescued with autologous stem cell support. 
Patients and methods

Patients
PBSC mobilization and apheresis
The PBSC mobilization schedule was begun at least 30 days after the last dose of chemotherapy. For mobilization of stem cells, s.c. G-CSF (10 mg per kg per day for 5 days) was given. Using either a peripheral vein or a Majurkar-type subclavian catheter, the apheresis procedures were performed on days-3, -2 and -1, using a Haemonetics V-50 PLUS machine (Haemonetics Corporation, Braintree, MA, USA) or a Baxter C-3000 PLUS machine (Baxter Healthcare, Deerfield, IL, USA), and the Spin-Nebraska protocol. 7 The apheresis objective was to reach at least 1 Â 10 6 viable CD34 þ cells/kg. 
Conditioning and autografting
Apheresis product preservation, studies and infusion
The products of the apheresis and 1 ml aliquots were kept in ACD-A (Baxter Healthcare) at 4 1C, in 300 ml transfer packs (Baxter Healthcare) composed of gas impermeable, polyvinyl chloride plastic film for up to 72 h. Enumeration of the total white mononuclear cells and CD34 positive cells was performed by flow cytometry 8 in an EPICS Elite ESP apparatus (Coulter Electronics, Hialeah, FL, USA), using for the latter subpopulation the anti-CD34 MoAb HPCA-2 (Becton Dickinson, San Jose´, CA, USA), gating in a propidium iodide-excluding CD45( þ ) mononuclear cell population according to forward and 901 angle light scattering. Additional viability studies of the mononuclear cell used propidium iodide exclusion and anti-cell antibodies on a flow cytometer. No purging procedures were performed. The apheresis products obtained on days-3, -2 and -1 were reinfused to the patients on days 0, þ 1 and þ 2, respectively, after keeping them in the conventional blood bank refrigerator.
Criteria for response
The criteria for response were the following: CR was defined as the absence of paraprotein on serum electrophoresis and 5% or fewer plasma cells in the marrow. Very good partial response was defined as a decrease of 90% in the serum paraprotein level, PR as a decrease of 50% in the serum paraprotein level and minimal response as a decrease of 25% in the serum paraprotein level. 4 
Results
Patients
Twenty-six patients were included in the study, 13 females and 13 males. The median age was 54 years (range 42-66). The type of paraprotein was IgG in 16 cases, IgA in 6 cases and light chain disease in 2 cases (both kappa). Associated amyloidosis was found in one case. According to the International Staging System, 9 21 patients were in stage I, three in stage II and two in stage III (see Table 1 ). All patients had been treated before the autograft as follows: six with thalidomide/dexamethasone (thal/dex), 11 with bortezomib-containing regimens, nine with VCR/adriamycin/DHAP and five with other schedules. At the time of the transplant, 11 patients were on CR, five in very good partial response, 12 in PR and three in minimal response. The amount of paraprotein at the time of the transplant has a median of 2.3 g per 100 ml (range 0-4.6).
PBSC mobilization and apheresis A median of three apheresis sessions was needed to collect a minimum of 1 Â 10 6 CD34 viable cells per kg of the recipient; 10 the range was 2-4 sessions to obtain enough CD34 þ cells.
Conditioning and autografting
All patients were conditioned with i.v. melphalan. In cases in which more than three apheresis sessions were needed to obtain a minimum of 1 Â 10 6 CD34 viable cells per kg of the recipient, the dose of melphalan was adjusted to 180 mg/m 2 (90% of the planned dose).
Apheresis product studies
The median number of transplanted CD34 viable cells was 7.56 Â 10 6 CD34 viable cells per kg of the recipient; the range was 0.92-14.8. In all cases, the viability of the CD34 cells was above 85% before being reinfused to the patients.
Engraftment and response
The time to achieve more than 0.5 Â 10 9 /l granulocytes had a median of 27 days (range 0-53), whereas the time to recover more than 20 Â 10 9 /l plts had a median of 37 days (range 0-73). Of the 26 patients autografted, 19 achieved a CR, six a very good partial response, five a PR and one a minimal response; the number of CR þ very good partial response before and after the autograft increased from 16 (51%) to 25 (81%) (see Figure 1 ). The amount of abnormal paraprotein dropped from a median of 2.3 g per 100 ml before the transplant to a median of 0.4 g per 100 ml. The 100-day mortality was 9.6% (3 of 31 transplants). Two patients died at day þ 9 and as a result of sepsis during granulocytopenia and one died at day þ 100 from a myocardial infarction. The median post-transplant overall survival has not been reached, being above 76 months, whereas the 76-month overall survival is 80% (see Figure 2) . Relapses presented after 10/31 autografts, a median of 34 months after the procedure; five patients were rescued with a second autograft and two were given an Allo-SCT from an HLA-identical sibling. Patients with a paraprotein at the time of transplant of less than 1 g per 100 ml had a better overall survival than those with more than 1 g per100 ml (see Figure 3 ). The differences on the long-term outcome of patients with an ISS of 1, 2 or 3 were analyzed and found to be NS, probably because of the low number of patients included in each group. The overall survival results of this study were compared with those of a historical control published earlier, 4 in a group of 23 patients treated with melphalan/prednisone. These survival results are substantially better than those of a historical control in a group of 23 patients treated in the same institution with melphalan/ prednisone, in which we observed a median survival of 33 months and a 72-month survival of 30% (Po0.01). 4 The autograft procedure was started in an outpatient basis in all patients; however, four were admitted to the hospital as a result of amebic colitis, 11 Pseudomona aeruginosa sepsis, cerebrovascular episode and soft-tissue abscess, one case each. Autografting in myeloma A López-Otero et al
Discussion
High-dose melphalan with autologous hematopoietic SCT improves response rates and survival in MM. [12] [13] [14] This is despite the fact that, unlike other hematological malignancies treated with high-dose therapy and autotransplantation, autografted MM patients continue to relapse several years after transplantation and the procedure is not curative in the majority of patients. [12] [13] [14] However, patients surviving for several years with an essentially normal quality of life may be considered to be operationally cured. In addition, unlike with other hematological malignancies relapsing after an auto SCT, recurrent disease can be treated with novel agents or repeat high-dose chemotherapy and Auto-or Allo-SCT and long-term survival is seen in a number of patients after relapse. [12] [13] [14] Although tandem transplantation is clearly superior to a single autograft, it is unclear whether this should be performed for all patients routinely or only for those not attaining CR after one transplant. It is also unclear whether novel agents should be used before transplantation or reserved for relapse. Despite their excellent activity, up to now, there is no convincing evidence that novel agents, such as thalidomide, bortezomib and lenalidomide can replace high-dose chemotherapy and SCT, and the best strategy is to use all options in all eligible patients at appropriate stages of the disease. [12] [13] [14] The most common indication for auto-SCT in the United States is MM. 14 Transplants, however, are resource intensive because myeloblative therapy always results in granulocytopenia and thrombocytopenia. Approximately 80% of transplant costs accrue during the in-hospital stay. Moreover, the hospital environment may be colonized with antibiotic-resistant bacteria, which can result in hospitalacquired infections for adult inpatients. Similar to that in the Mayo Clinic, 14 our Auto-SCT program, started in 1993, has focused on conducting the grafts on an outpatient basis, including outpatient conditioning, outpatient stem cell infusions and outpatient post-infusion medical care. [15] [16] [17] On the other hand, by sparing stem cell freezing procedures and by keeping the cells in a conventional blood bank refrigerator, 18 we have been able to substantially cut down the costs of autografting. 10 All these changes have resulted in cost-savings that are critical mainly in developing countries; 10,15-18 accordingly, we have been able to calculate that the median cost of an Auto-SCT in our country using this method is around US$ 15 000.00, a figure substantially lower than that informed from the United States, 19 and a figure that is also lower than the cost of the continued treatment with novel anti-myeloma agents, such as lenalidomide, bortezomib and others; these data are to be taken into account when considering option treatments, mainly in developing countries. 20 The non-cryopreserved storage of hematopoietic stem cells is not a standard practice and we have shown that these cells can be stored for up to 72 h at 4 1C;
18 however, this practice may be related to the engraftment times that we have observed in this study, which seem to be longer than in other published series.
By using this simplified and affordable autografting procedure, we have been able to reproduce the results obtained by grafting MM patients in more privileged societies and, as a result, we have been able to offer this therapeutic option to patients living in Me´xico who could not afford the cost of a conventional autografting procedure. The results of this study in MM patients are acceptable and clearly superior to those obtained with conventional chemotherapy in the same institution. 4, 13 In summary, high-dose chemotherapy rescued with Auto-SCT is a valid treatment option for patients with MM; when conducted with appropriate modifications, including outpatient procedures, it is also affordable and represents a true therapeutic option even for individuals living in developing countries.
